
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is projected to continue advancing its pipeline and drive growth, with potential upcoming catalysts such as dose escalation results from Phase 1b trials for its lead programs expected in early 2027 and commencement of IND-enabling studies for earlier stage programs. Their financial results for 2025 showed a wider net loss than estimated, but with ample resources to fund operations into 2029. While risks such as negative clinical results and competitive pressures exist, with adjusted operating expenses and a strong pipeline, I maintain my Buy rating and increased my 12-month price target to $33 per share.
Bears say
Aktis Oncology is facing several challenges, including competition from other companies presenting data on their B7H3- or NECTIN-4-targeted ADCs at a recent conference, which may hinder the success of its own RCT in development. Additionally, while the imaging and dosimetry results for AKY-2519 support its clinical development, the company's pipeline and potential for revenue generation are still highly dependent on the success of this lead asset. Lastly, the company's high valuation and potential dilution risk pose further concerns for investors.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares